Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Macitentan (Primary) ; Tadalafil
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms OPTIMA
- Sponsors Actelion Pharmaceuticals
- 28 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2020.
- 28 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History